JPRN-UMIN000042883招募中未知
Coronary Plaque Characterization by Near-infrared Spectroscopy for Identification of Plaque Vulnerability: Association with Coronary Computed Tomographic Angiography - Coronary Plaque Characterization by Near-infrared Spectroscopy for Identification of Plaque Vulnerability: Association with Coronary Computed Tomographic Angiography
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Chronic kidney disease manifested by an estimated glomerular filtration rate of < 40 mL/min/1.73 m2 2. Significant left main disease 3. Previously stented lesions. In addition, patients with extensively severe stenotic lesions which was anticipated difficulty in advancing the NIRS-IVUS catheter without plain old balloon angioplasty (POBA) using more than 2.0 mm of diameter were excluded. 4. Extremely calcified lesions treated with atheroablative device (e.g. Rotablator and Diamondback 360).
研究者
相似试验
招募中
不适用
Coronary Plaque Characterization by Near-infrared Spectroscopy for Identification of Plaque Vulnerability: Association with Coronary Computed Tomographic AngiographyIschemic Heart DiseaseJPRN-UMIN000043115Gifu Heart Center200
已完成
不适用
Coronary Artery Plaque Characterisation with Non-invasive Multi-Slice Computed Tomography and Invasive Intravascular Ultrasound and Optical Coherence Tomography in Patients with Acute Coronary Syndromes Without ST-segment Elevatio10011082atherosclerosisNL-OMON36442niversitair Medisch Centrum Groningen50
已完成
2 期
SPECTACL: SPECTroscopic Assessment of Coronary LipidAngina, UnstableMyocardial InfarctionAngina PectorisNCT00330928Infraredx106
已完成
3 期
High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS)anginaheart attackhigh blood lipidshigh cholesterolVessels supplying the heart with blood1001108210013317NL-OMON48805Amgen43
进行中（未招募）
1 期
Imaging of Coronary Plaques in Subjects Treated With EvolocumabDyslipidemiaEUCTR2017-003236-37-DEAmgen Inc.150